Deals this week: Luminex Corporation, DarioHealth, Halo Labs

4 January 2019 (Last Updated January 4th, 2019 10:45)

Luminex Corporation has completed the acquisition of MilliporeSigma's flow cytometry business in a $75m deal. 

Luminex Corporation has completed the acquisition of MilliporeSigma’s flow cytometry business in a $75m deal.

The acquisition will strengthen Luminex’s existing flow-based detection systems offerings and improve its interaction with researchers performing cellular analysis.

Luminex is a biotechnology company and MilliporeSigma is a life sciences and technology company. Both companies are based in the US.

DarioHealth has entered an agreement to distribute Better Living Now’s blood glucose monitoring system and digital health products.

Better Living Now will purchase and distribute DarioHealth’s products to its customers, who will also receive a complete diabetes management programme, including coaching via the DarioEngage health platform on a subscription basis.

DarioHealth is a medical device company based in Israel, while Better Living Now is a healthcare products supplier based in the US.

Halo Labs has raised $5.6m in a series B financing round led by Research Corporation Technologies.

“The company will be eligible to receive up to $32.5m in upfront and milestone payments.”

Proceeds will be used to commercialise Halo Labs’ subvisible particle analysis instrument Horizon and for the further development of its product pipeline.

Halo Labs is a scientific instrumentation company based in Canada.

AIT Therapeutics plans to sign a definitive agreement to licence the commercialisation rights for its new nitric oxide delivery system, GeNOvent, to an unnamed partner.

The company will out-license GeNOvent’s commercialisation rights to treat persistent pulmonary hypertension (PPHN) in newborns and other related indications.

AIT will develop, manufacture, submit regulatory applications and carry out system repairs for the product, while the partner will perform commercial sales and marketing tasks.

The company will be eligible to receive up to $32.5m in upfront and milestone payments. It will also be eligible to receive between 15% and 20% in royalties based on the product’s annual sales.

AIT Therapeutics is a US-based medical device company.